How should private equity firms present case studies under the SEC Marketing Rule?
Under the SEC Marketing Rule, a private equity case study in fundraising materials generally has to be fair and balanced, backed by claims the adviser can substantiate and selected without cherry-picking, while extracted and hypothetical performance carry extra conditions. A five-part structure (situation, lever, evidence, result, what did not work) helps present initiatives, including an unclosed data license, accurately.
The short answer: it depends on whether the case study is an advertisement
Whether the SEC Marketing Rule governs a private equity case study depends on who sends it, to whom and why. For an SEC-registered investment adviser, a case study inside materials that offer a fund to prospective investors will often be part of an advertisement. When it is, the case study has to be fair and balanced, its material claims have to be ones the adviser can substantiate, and any performance it shows, including single-deal or projected figures, brings extra conditions. Compliance counsel decides which documents are in scope.
The rule is Rule 206(4)-1 under the Investment Advisers Act of 1940, codified at 17 CFR 275.206(4)-1. Read the rule text, the SEC's adopting release and the staff FAQs with your compliance team. This page summarizes the themes that matter for case studies and offers a structure for writing them; it does not replace that reading.
What the rule says, in plain terms
The rule sets general prohibitions that apply to every advertisement. In plain language, an advertisement may not:
- Include an untrue statement of material fact, or leave out a fact needed to stop a statement from misleading.
- Include a material statement of fact the adviser has no reasonable basis to believe it can substantiate if the SEC asks.
- Create an untrue or misleading implication about the adviser.
- Discuss potential benefits without fair and balanced treatment of material risks or limitations.
- Refer to specific investment advice in a way that is not fair and balanced.
- Include or exclude performance results, or choose time periods, in a way that is not fair and balanced.
- Otherwise be materially misleading.
Compliance teams generally treat a portfolio company case study as a reference to specific investment advice, which brings in the fair-and-balanced standard. Beyond the general prohibitions, the rule adds conditions for particular kinds of performance. Three come up constantly in case studies:
- Extracted performance, meaning results of a subset of a fund's investments, such as one deal's MOIC. The rule ties it to the results of the total portfolio it was drawn from.
- Hypothetical performance, meaning results not actually achieved, which can include projections and targets. It is permitted only under conditions, including policies tailored to the intended audience.
- Gross and net results, where gross figures are expected to appear with net figures.
Each has detailed conditions, so take the exact wording from the rule text rather than from a summary.
How the rule applies in common case-study situations
| Situation | What to check | Outcome to confirm with compliance |
|---|---|---|
| A deck shows only the three strongest exits as operating case studies | Selection criteria, and whether weaker deals were left out | Consistent criteria, disclosed, or a fuller list available |
| A case study gives one deal's gross MOIC and IRR | Extracted performance and gross-versus-net conditions | Total-fund results and net figures alongside |
| An EBITDA bridge credits growth to the operating team | Substantiation file; add-ons, market tailwinds and other drivers | Attribution wording, plus backup you can produce on request |
| A pricing initiative is described as expected to add margin | Whether the projection counts as hypothetical performance | Labeled as a target with assumptions, or removed |
| A portfolio company is exploring a data license that has not closed | Its actual stage and any confidentiality obligations | Described as in progress, with no value or revenue implied |
| A closed data license appears in the results | One-time versus recurring; contract value versus recognized revenue | Shown as non-recurring, with the term disclosed |
| A portfolio CEO quote praises the operating team | Whether the statement is a testimonial or endorsement under the rule | Required disclosures added, or the quote removed |
Pricing work is one of the initiatives that most often lands in these decks; the guide to pricing as a value creation lever shows what such a review produces and what it does not.
A fair case-study structure: situation, lever, evidence, result, what did not work
Writing each case study in these five parts, in this order, keeps it specific and balanced.
- Situation. The company's position at entry in facts an LP can check: revenue band, margin, systems and the problem the plan targeted.
- Lever. What the operating team and management actually did, who led it and when. Name the firm's role honestly; management usually carried most of the work.
- Evidence. The documents behind each claim: board minutes, KPI history, signed agreements, invoices. If you could not produce it on request, cut the claim.
- Result. Measured outcomes, with the period, the basis (reported, adjusted or run-rate) and the other drivers that contributed.
- What did not work. The initiative that stalled, the cost that overran, the assumption that proved wrong. This part does more for credibility than any chart.
LPs ask for exactly this kind of evidence when they test an operating model, as the guide to how LPs evaluate operating partner models describes.
How to describe a data license before and after it closes
A data license passes through distinct stages, and the wording should match the stage. Nothing is binding until the company agrees price and terms and signs, so an exploratory process is not an asset to count.
| Stage | Accurate wording | Wording to avoid |
|---|---|---|
| Screening | Assessing whether records may be licensable | New revenue stream identified |
| Data inventory under way | Inventorying systems, history and rights | Dataset valued at a figure |
| Price and terms agreed by the company | Terms set; no buyer contract yet | Signed deal |
| Under buyer review | In discussions with potential licensees | Pipeline worth a figure |
| Signed and paid | One-time license payment received; licensee not named | Recurring data revenue |
Public filings show why contract value and revenue need separating. In its February 2024 IPO registration statement, Reddit disclosed data licensing arrangements entered in January 2024 with an aggregate contract value of $203.0 million over terms of two to three years, and said it expected to recognize at least $66.4 million of that in 2024. The same separation of total value, term and revenue in the period is the fair way to present any license in a case study. For how a one-time license interacts with earnings quality, see the controller's guide to booking a one-time license.
Disclosure and consent good practice
- Get the portfolio company's written approval before naming it or describing its initiative. Data licenses usually carry confidentiality terms, and the licensee is normally not named.
- Keep a substantiation file for each case study: source documents, the calculation and who signed off.
- Footnote one-time items as non-recurring and give the period they fell in.
- If anyone at the firm receives a referral reward connected to a portfolio company, check the LPA's fee and conflicts provisions and disclose it as counsel advises.
- Date every case study and review it before each new fundraising round.
Questions to ask your compliance counsel
- Which of our fundraising decks, data room documents and DDQ answers count as advertisements under the rule?
- Do our case-study selection criteria hold up if every comparable deal is set beside the ones we show?
- Which figures in our case studies are extracted or hypothetical performance, and what has to accompany them?
- How should a non-recurring item such as a data license appear in an EBITDA bridge?
- Do any portfolio CEO quotes count as testimonials or endorsements, and what follows if they do?
- What substantiation file do we need for each case study, and who maintains it?
DDQ responses raise many of the same questions; the guide to ILPA DDQ value creation questions covers that side.
This is general information, not legal, tax or financial advice. Confirm with your own counsel or compliance consultant before acting.
Next step
If your operating team screens portfolio companies for data licensing, describe that work in the stage language above and nothing stronger. When a company meets the who qualifies baseline, an operating partner can register as a partner and introduce the company; the operating partners page explains how the program works on the sponsor side.
- Step 1Share your linkSend your personal link to a company you know.
- Step 2Company appliesThe company applies itself at /apply.
- Step 3Buyer selects and paysThe buyer selects and pays for the data and SourceX receives its fee.
- Step 4You get your rewardYour share of SourceX fees becomes payable.
Common questions
Does the Marketing Rule apply to updates sent only to existing LPs?
It depends on the content. The rule's definition of an advertisement centers on communications that offer the adviser's services, including new or additional services to existing investors, so a routine quarterly report may be treated differently from a deck promoting a successor fund. Compliance counsel should classify each document type. Many firms apply the same fair-presentation standards to both to keep their messages consistent.
Can a GP mention a portfolio company data license that has not closed?
It can describe the work accurately if the company agrees, but it should not present an unclosed license as revenue, value or a likely outcome. Use stage language such as screening or inventory in progress, avoid any figure, and remember that nothing is binding until the company signs. Ask compliance whether a projected license value would count as hypothetical performance before it appears anywhere.
Is a portfolio company case study the same as a testimonial?
Not necessarily. A case study the GP writes about one of its investments is generally treated as a reference to specific investment advice, which must be fair and balanced. A quote from a person praising the adviser may be a testimonial or an endorsement, which brings separate disclosure conditions. Compliance should review any third-party statement before it appears in fundraising materials.
How should a one-time data license appear in a case-study EBITDA bridge?
As a separate non-recurring item, labeled with its period and kept out of run-rate or adjusted EBITDA unless the firm's methodology and the company's auditors support including it. Pair it with a plain description: a one-time payment for licensed records, with the licensee unnamed. Folding it into operating improvement would overstate what the operating plan delivered.
Do we need the portfolio company's permission to describe its data license?
In practice, yes. The company owns its records and signs the license, and license agreements usually include confidentiality terms that can restrict describing the buyer, the price or the scope. Get the company's written approval for the exact wording, keep the licensee unnamed, and check whether the shareholder agreement or the company's own policies add conditions.
Related pages
- Referral opportunities for private equity operating partners
- Controller at a PE-backed company: booking a one-time license
- How LPs evaluate operating partners, and what to prepare before a raise
- How to answer value creation questions in an ILPA due diligence questionnaire
- Pricing as a value creation lever in private equity, and what a pricing review surfaces
- Which US businesses are a fit for a SourceX data licensing introduction
Free resources
- IRR calculator — Internal rate of return on annual cash flows.
- Business valuation calculator — Enterprise and equity value from EBITDA, your multiple, cash and debt.
- Portfolio data opportunity scanner — Screen several companies in one session.
- All free tools · MCP resource center
By SourceX Partnerships Team · Published 2026-10-09 · Updated 2026-10-09
Know a US company with valuable proprietary data?
Become a referral partner from anywhere we support, get your link and introduce an owner or authorized decision-maker.
Refer a company →I own a business
Explore licensing your company's data to AI developers worldwide. Start a short assessment; no uploads needed.
Start an assessment